203 related articles for article (PubMed ID: 17613700)
1. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
[TBL] [Abstract][Full Text] [Related]
2. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
[TBL] [Abstract][Full Text] [Related]
3. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
[TBL] [Abstract][Full Text] [Related]
4. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
[TBL] [Abstract][Full Text] [Related]
5. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
[TBL] [Abstract][Full Text] [Related]
6. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions.
Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J
ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638
[TBL] [Abstract][Full Text] [Related]
7. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
[TBL] [Abstract][Full Text] [Related]
8. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
Szebeni J
Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
[TBL] [Abstract][Full Text] [Related]
9. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
[TBL] [Abstract][Full Text] [Related]
10. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function.
Szebeni J; Baranyi L; Sávay S; Bodó M; Milosevits J; Alving CR; Bünger R
Am J Physiol Heart Circ Physiol; 2006 Mar; 290(3):H1050-8. PubMed ID: 16214844
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
[TBL] [Abstract][Full Text] [Related]
12. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
Szebeni J; Storm G
Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
Szebeni J
Drug Discov Today; 2018 Mar; 23(3):487-492. PubMed ID: 29326077
[TBL] [Abstract][Full Text] [Related]
14. The interaction of liposomes with the complement system.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 1998; 15(1):57-88. PubMed ID: 9523086
[TBL] [Abstract][Full Text] [Related]
15. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.
Őrfi E; Mészáros T; Hennies M; Fülöp T; Dézsi L; Nardocci A; Rosivall L; Hamar P; Neun BW; Dobrovolskaia MA; Szebeni J; Szénási G
Int J Nanomedicine; 2019; 14():1563-1573. PubMed ID: 30880965
[TBL] [Abstract][Full Text] [Related]
16. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.
Mészáros T; Csincsi ÁI; Uzonyi B; Hebecker M; Fülöp TG; Erdei A; Szebeni J; Józsi M
Nanomedicine; 2016 May; 12(4):1023-1031. PubMed ID: 26733258
[TBL] [Abstract][Full Text] [Related]
17. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
[TBL] [Abstract][Full Text] [Related]
18. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor.
Dézsi L; Mészáros T; Kozma G; H-Velkei M; Oláh CZ; Szabó M; Patkó Z; Fülöp T; Hennies M; Szebeni M; Barta BA; Merkely B; Radovits T; Szebeni J
Geroscience; 2022 Apr; 44(2):597-618. PubMed ID: 35146583
[TBL] [Abstract][Full Text] [Related]
19. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production.
Moghimi SM; Hamad I; Andresen TL; Jørgensen K; Szebeni J
FASEB J; 2006 Dec; 20(14):2591-3. PubMed ID: 17065229
[TBL] [Abstract][Full Text] [Related]
20. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
Szebeni J; Muggia F; Gabizon A; Barenholz Y
Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
